Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities

S Yoda, I Dagogo-Jack, AN Hata - Pharmacology & therapeutics, 2019 - Elsevier
Targeted therapies have changed the landscape of treatments for non-small cell lung cancer
(NSCLC). Specific targeted therapies have been approved for NSCLC patients harboring …
被引用次数：67 相关文章

[引用][C] Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities

S Yoda, I Dagogo-Jack, AN Hata - Pharmacology & Therapeutics, 2019 - cir.nii.ac.jp
Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future
opportunities | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …

Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities.

S Yoda, I Dagogo-Jack, AN Hata - Pharmacology & Therapeutics, 2018 - europepmc.org
Targeted therapies have changed the landscape of treatments for non-small cell lung cancer
(NSCLC). Specific targeted therapies have been approved for NSCLC patients harboring …

Targeting oncogenic drivers in lung cancer: Recent progress, current challenges and future opportunities

S Yoda, I Dagogo-Jack… - Pharmacology & …, 2019 - pubmed.ncbi.nlm.nih.gov
Targeted therapies have changed the landscape of treatments for non-small cell lung cancer
(NSCLC). Specific targeted therapies have been approved for NSCLC patients harboring …